Care at NUH

Doctor Details

Find a Doctor
Doctor Detail

Dr Natalie Ngoi

Photo of Dr Natalie Ngoi


  • Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Clinical Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore


MBBS (Hons), MRCP (UK), M.Med (Int Med)


Medical Oncology

Special Interests:

Precision Oncology, Gynaecologic Oncology, Genitourinary Oncology, Drug Development 


Dr Natalie Ngoi is a Consultant Medical Oncologist with a keen interest in developmental therapeutics and a subspecialty interest in Gynecologic and Genitourinary Cancers. She graduated with Honours from the Yong Loo Lin School of Medicine at the National University of Singapore in 2012 and continued her post-graduate training in Internal Medicine at the National University Health System Singapore. Dr Ngoi completed her Medical Oncology fellowship training at the National University Health System in Singapore in 2018, and is accredited by ACGME-I, the Specialist Accreditation Board and the Singapore Medical Council. 

In 2019, Dr Ngoi was awarded the National Medical Research Council Singapore Research Training Fellowship Grant and furthered her training in early drug development at the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center between 2021 to 2022, where she studied synthetic lethal strategies in drug development.

Dr Ngoi has an interest in clinical and translational research in Gynaecologic Oncology. She has multiple publications in peer-reviewed journals in this area and is an invited journal reviewer in this field. She serves as an active member of the Gynecologic Cancer Group Singapore and Asia Pacific Gynecologic Oncology Trials Group. 


  • 2023 - ESMO Merit Travel Grant, ESMO Asia, Singapore
  • 2023 - ESMO Research Fellowship – Translational Focus, awarded at ESMO Congress, Madrid
  • 2023 - National Medical Research Council Singapore, New Investigator Grant
  • 2022 - Best Poster Award, Developmental Therapeutics, ESMO Congress, Paris
  • 2022 - Conquer Cancer ® The ASCO Foundation Merit Award
  • 2019 - National Medical Research Council Singapore, Research Training Fellowship

Journals & Publications

  1. Tan TZ, Ye J, Yee CV, Lim D, Ngoi NYL, Tan DSP, et al. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine. 2019;50:203-10.
  2. Ngoi NYL, Choong C, Lee J, Bellot G, Wong ALA, Goh BC, et al. Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer. Cancers (Basel). 2020;12(3).
  3. Ngoi NYL…Jeyasekharan AD, on behalf of the National University Cancer Institute of Singapore (NCIS) workflow team. A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore. Annals of Oncology 2020 Mar 31;S0923-7534(20)36410-3.
  4. Ngoi NYL, Sundararajan V, Tan DSP.Exploiting Replicative Stress in Gynecological Cancers as a Therapeutic Strategy. International Journal of Gynecologic Oncology. Published Online First: 22 June 2020. doi: 10.1136/ijgc-2020-001277
  5. Ngoi NYL…Tan DSP. A multicentre phase II randomized trial of Durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell carcinoma (MOCCA). International Journal of Gynecologic Oncology. Published Online First: 25 June 2020. doi: 10.1136/ijgc-2020-001604
  6. GCHJ… Ngoi NYL.. Soo RA. Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. Lung Cancer. 2020 Aug;146:145-153. doi: 10.1016/j.lungcan.2020.05.020.
  7. Ngoi NYL….Tan DSP. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01). Int J Radiat Oncol Biol Phys. 2020 Oct 9:S0360-3016(20)34384-4. doi: 10.1016/j.ijrobp.2020.09.059.
  8. Zhao JJ…Ngoi N, and Wong A. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience. Oncology: 1-11, 2021.
  9. Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, et al. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J Gynecol Oncol. 2021;32(2):e31.
  10. Wong A, Vellayappan B, Cheng L, Zhao JJ, Muthu V, Asokumaran Y, Low JL, Lee M, Huang YQ, Kumarakulasinghe NB, Ngoi N, Leong CN, Chua W, and Thian YL. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri. Cancers (Basel) 13, 2021.

Professional Memberships

  • Member, Singapore Society of Oncology
  • Member, American Society of Clinical Oncology
  • Member, GyneCologic Cancer Group Singapore
  • Member, European Society of Medical Oncology

Last updated on
Best viewed with Chrome 79.0, Edge 112.0, Firefox 61.0, Safari 11
National University Health System
  • National University Hospital
  • Ng Teng Fong General Hospital
  • Alexandra Hospital
  • Jurong Community Hospital
  • National University Polyclinics
  • Jurong Medical Centre
  • National University Cancer Institute, Singapore
  • National University Heart Centre, Singapore
  • National University Centre for Oral Health, Singapore
  • NUHS Diagnostics
  • NUHS Pharmacy
  • Yong Loo Lin School of Medicine
  • Faculty of Dentistry
  • Saw Swee Hock School of Public Health
Back to Top